AI Terminal
ALLERGY THERAPEUTICS PLC
Director's Dealing • Nov 20, 2020
7477_dirs_2020-11-20_1e773395-cdde-4e6b-9e04-219f7530bd82.html
Director's Dealing
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 0593G
Allergy Therapeutics PLC
20 November 2020
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Group")
Grant of Awards under Long Term Incentive Plan
Allergy Therapeutics (AIM:AGY), the fully integrated pharmaceutical company specialising in allergy vaccines, announces that, on 20 November 2020, pursuant to the Company's Long Term Incentive Plan ("LTIP") the following conditional awards of shares of 0.1 pence each were made to Executive Directors at a nominal cost of 0.1 pence each (the "Awards").
| Executive Director | Number of Conditional shares awarded |
| Manuel Llobet | 900,000 |
| Nick Wykeman | 450,000 |
The Awards have been granted in accordance with the LTIP rules and vesting is conditional on the satisfaction of two performance measures over a three-year period:
| Measure: | Target Range: |
| Compounded annual earnings growth rate (EBITDA) pre R&D spend | 7.5% - 17.5% |
| Compounded annual share price growth | 15% - 40% |
Following the above share transactions, the Executive Directors hold the following:
| Director | Unvested LTIP Awards | Low cost Share Options | Interest in Ordinary Shares |
| Manuel Llobet | 3,600,000 | 211,250 | 3,325,000 |
| Nicolas Wykeman | 1,800,000 | 211,250 | 300,000 |
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Manuel Llobet
2
Reason for the notification
a)
Position/status
Manuel Llobet - Chief Executive Office and PDMR
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
ALLERGY THERAPEUTICS PLC
b)
LEI
LEIR97215202003301009534776
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Conditional award of shares under the Company's Long Term Incentive Plan
b)
Identification code
GB00B02LCQ05
c)
Nature of the transaction
Grant of Conditional Awards
d)
Price(s) and volume(s)
| Award | Price(s) | Volume(s) |
| Conditional Shares | £0.001 | 900,000 |
e)
Aggregated information
n/a
f)
Date of the transaction
19 November 2020
g)
Place of the transaction
Outside a trading venue
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Nick Wykeman
2
Reason for the notification
a)
Position/status
Nick Wykeman - Chief Financial Officer and PDMR
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
ALLERGY THERAPEUTICS PLC
b)
LEI
LEIR97215202003301009534776
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Conditional award of shares under the Company's Long Term Incentive Plan
b)
Identification code
GB00B02LCQ05
c)
Nature of the transaction
Grant of Conditional Awards
d)
Price(s) and volume(s)
| Award | Price(s) | Volume(s) |
| Conditional Shares | £0.001 | 450,000 |
e)
Aggregated information
n/a
f)
Date of the transaction
19 November 2020
g)
Place of the transaction
Outside a trading venue
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Chief Financial Officer
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley, Emma Earl, Corporate Finance
Erik Anderson, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / David Daley / Nicholas Brown / Olivia Manser
Stern Investor Relations, Inc.
+1 212 362 1200
Christina Tartaglia
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international specialty pharmaceutical group focussed on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines, that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which has achieved double digit compound annual growth since formation, employs c.600 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHBXBDBISDDGGG